Sugi Predict

Sugi Predict / Compounds / SCHEMBL1935308

SCHEMBL1935308

SCHEMBL1935308

CN(Cc1ccc(CO)cc1)C(=O)OC(C)(C)C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PPARG P37231 1/20 0.46
▸ PPARA Q07869 1/20 0.46
▸ CTSL P07711 1/20 0.44
▸ CTSB P07858 1/20 0.44
▸ CTSS P25774 1/20 0.44
▸ RIPK1 Q13546 2/20 0.42
▸ HTR2C P28335 1/20 0.42
▸ SLC6A4 P31645 1/20 0.42
▸ HDAC3 O15379 1/20 0.40
▸ HDAC1 Q13547 1/20 0.40
▸ HDAC2 Q92769 1/20 0.40
▸ NCOR2 Q9Y618 1/20 0.40
▸ ALDH1A1 P00352 3/20 0.40
▸ HTT P42858 2/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ RAB9A P51151 3/20 0.39
▸ GLS O94925 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ NPC1 O15118 2/20 0.39
▸ CA12 O43570 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14829724 0.89 PPARG (0.43) PPARGPPARACTSLCTSBCTSS
SCHEMBL23448763 0.88 HRH3 (0.44) CTSLCTSBCTSSRIPK1HTR2C
SCHEMBL1109788 0.87 PPARA (0.49) PPARACTSLCTSBCTSSRIPK1
SCHEMBL2229917 0.87 MTOR (0.48) CTSLCTSBCTSSRIPK1HTR2C
SCHEMBL25546128 0.87 HSP90AA1 (0.43) CTSLCTSBCTSSRIPK1HTR2C
SCHEMBL8139521 0.85 TPSAB1 (0.47) CTSLCTSBCTSSRIPK1HTR2C
SCHEMBL30264860 0.85 ALDH1A1 (0.57) RIPK1HTR2CSLC6A4ALDH1A1HTT
SCHEMBL1935742 0.85 AKT1 (0.43) CTSLCTSBCTSSRIPK1HTR2C
SCHEMBL7430459 0.85 RIPK1 (0.59) RIPK1HTR2CSLC6A4ALDH1A1
SCHEMBL5726780 0.85 HTR2C (0.41) CTSLCTSBCTSSRIPK1HTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3886904-B1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-04-22 — — EP disclosed
US-20250163042-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-05-22 — — US disclosed
US-12258355-B2 Probes for imaging huntingtin protein CHDI FOUNDATION, INC. (US) 2025-03-25 — — US disclosed
US-12258341-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2025-03-25 — — US disclosed
US-20240239777-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-07-18 — — US disclosed
US-11807636-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-11-07 — — US disclosed
US-11807636-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-11-07 — — US disclosed
CN-116655618-A Probes for imaging huntingtin CHDI基金会股份有限公司 2023-08-29 — — CN disclosed
US-20230212190-A1 PROBES FOR IMAGING HUNTINGTIN PROTEIN CHDI FOUNDATION, INC. 2023-07-06 — — US disclosed
US-20230212190-A1 PROBES FOR IMAGING HUNTINGTIN PROTEIN CHDI FOUNDATION, INC. 2023-07-06 — — US disclosed
US-20140073627-A1 BRADYKININ B1 ANTAGONISTS EVOTEC AG (DE) 2014-03-13 — — US disclosed
US-8623859-B2 Bradykinin B1 antagonists EVOTEC AG (DE) 2014-01-07 — — US disclosed
US-8623859-B2 Bradykinin B1 antagonists EVOTEC AG (DE) 2014-01-07 — — US disclosed
US-8623859-B2 Bradykinin B1 antagonists EVOTEC AG (DE) 2014-01-07 — — US disclosed
US-20110201589-A1 NEW BRADYKININ B1 ANTAGONISTS EVOTEC AG (DE) 2011-08-18 — — US disclosed
US-20110201589-A1 NEW BRADYKININ B1 ANTAGONISTS EVOTEC AG (DE) 2011-08-18 — — US disclosed
US-20110201589-A1 NEW BRADYKININ B1 ANTAGONISTS EVOTEC AG (DE) 2011-08-18 — — US disclosed
EP-2331518-A1 NEW BRADYKININ B1 ANTAGONISTS Evotec AG (DE) 2011-06-15 — — EP disclosed
WO-2010020556-A1 NEW BRADYKININ B1 ANTAGONISTS EVOTEC NEUROSCIENCES GMBH (DE) 2010-02-25 — — WO disclosed
US-20060276433-A1 Hydrazone derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-12-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230212190-A1 PROBES FOR IMAGING HUNTINGTIN PROTEIN HTT, HYPK, HSPBP1 PPARG 3184/4885PPARA 4066/4885CTSL 4041/4885
US-12258341-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 PPARG 3050/4885PPARA 2130/4885CTSL 941/4885
US-20250163042-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 PPARG 3050/4885PPARA 2130/4885CTSL 941/4885
US-20240239777-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 PPARG 3050/4885PPARA 2130/4885CTSL 941/4885
US-11807636-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 PPARG 3050/4885PPARA 2130/4885CTSL 941/4885
US-20140073627-A1 BRADYKININ B1 ANTAGONISTS BDKRB1, BDKRB2, BRS3 PPARG 4773/4885PPARA 4126/4885CTSL 1241/4885
US-20060276433-A1 Hydrazone derivative APP, PRNP, HTT PPARG 507/4885PPARA 619/4885CTSL 4519/4885
US-12258355-B2 Probes for imaging huntingtin protein HTT, HYPK, HSPBP1 PPARG 3184/4885PPARA 4066/4885CTSL 4041/4885
US-20110201589-A1 NEW BRADYKININ B1 ANTAGONISTS BDKRB1, BDKRB2, BRS3 PPARG 4780/4885PPARA 4286/4885CTSL 1076/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.